drugset / Trial / NCT05210595
Optimal Dosage of Ticagrelor in Korean Patients With AMI
RandomizedParallel-groupOpen-labelTreatment
Summary
East Asian patients will be required optimal dose of newer P2Y12 inhibitor (ticagrelor) to determine the safer treatment and better outcome. Whether low dose of ticagrelorI is more adequate for clinical practice in Korea is unclear. Therefore, the investigators aim to evaluate efficacy and safety of low dose of ticagrelor in Acute Myocardial Infarction (AMI) undergoing percutaneous coronary intervention(PCI).
Timeline
- Start
- 2022-01-01
- Primary completion
- 2022-12-31
- Completion
- 2023-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Clopidogrel | Small molecule | 75 mg | — |
| Subject | Ticagrelor | Small molecule | 45 mg | Oral |
| Subject | Ticagrelor | Small molecule | 60 mg | Oral |